Key result
Elevated galectin-3 is linked to ~2.7-fold higher major cardiovascular events risk in nonischemic dilated cardiomyopathy.
Why the study?
Although several collagen turnover biomarkers are associated with myocardial fibrosis in nonischemic dilated cardiomyopathy, their clinical utility remains limited. Their association with replacement myocardial scarring by CMR and their ability to predict outcomes in conjunction with LGE required evaluation.
Do circulating collagen turnover biomarkers (Gal3, PICP, PIIINP) correlate with CMR late gadolinium enhancement and improve prediction of composite cardiovascular outcomes in patients with non-ischemic dilated cardiomyopathy?
Cohort (n=194)
CMR operators blinded to clinical and imaging data
No
Do circulating collagen turnover biomarkers (Gal3, PICP, PIIINP) correlate with CMR late gadolinium enhancement and improve prediction of composite cardiovascular outcomes in patients with non-ischemic dilated cardiomyopathy?
Answers are grounded in this paper and cite their sources.
In patients with non-ischemic dilated cardiomyopathy, circulating collagen turnover biomarkers (especially Galectin-3) strongly correlate with myocardial replacement fibrosis on CMR and provide incremental prognostic value alongside LGE for predicting major adverse cardiovascular events.
Background: Myocardial scarring is a primary pathogenetic process in nonischemic dilated cardiomyopathy (NIDCM) that is responsible for progressive cardiac remodeling and heart failure, severely impacting the survival of these patients. Although several collagen turnover biomarkers have been associated with myocardial fibrosis, their clinical utility is still limited. Late gadolinium enhancement (LGE) determined by cardiac magnetic resonance imaging (CMR) has become a feasible method to detect myocardial replacement fibrosis. We sought to evaluate the association between collagen turnover biomarkers and replacement myocardial scarring by CMR and, also, to test their ability to predict outcome in conjunction with LGE in patients with NIDCM. Method: We conducted a prospective study on 194 patients (48.7 ± 14.3 years of age; 74% male gender) with NIDCM. The inclusion criteria were similar to those for the definition of NIDCM, performed exclusively by CMR: (1) LV dilation with an LV end-diastolic volume (LVEDV) of over 97 mL/m2; (2) global LV dysfunction, expressed as a decreased LVEF of under 45%. CMR was used to determine the presence and extent of LGE. Several collagen turnover biomarkers were determined at diagnosis, comprising galectin-3 (Gal3), procollagen type I carboxy-terminal pro-peptide (PICP) and N-terminal pro-peptide of procollagen type III (PIIINP). A composite outcome (all-cause mortality, ventricular tachyarrhythmias, heart failure hospitalization) was ascertained over a median of 26 months. Results: Gal3, PICP and PIIINP were considerably increased in those with LGE+ (p < 0.001), also being directly correlated with LGE mass (r2 = 0.42; r2 = 0.44; r2 = 0.31; all p < 0.001). Receiver operating characteristic (ROC) analysis revealed a significant ability to diagnose LGE, with an area under the ROC of 0.816 for Gal3, 0.705 for PICP, and 0.757 for PIIINP (all p < 0.0001). Kaplan−Meier analysis showed that at a threshold of >13.8 ng/dL for Gal3 and >97 ng/dL for PICP, they were able to significantly predict outcome (HR = 2.66, p < 0.001; HR = 1.93, p < 0.002). Of all patients, 17% (n = 33) reached the outcome. In multivariate analysis, after adjustment for covariates, only LGE+ and Gal3+ remained independent predictors for outcome (p = 0.008; p = 0.04). Nonetheless, collagen turnover biomarkers were closely related to HF severity, providing incremental predictive value for severely decreased LVEF of under 30% in patients with NIDCM, beyond that with LGE alone. Conclusions: In patients with NIDCM, circulating collagen turnover biomarkers such as Gal3, PICP and PIIINP are closely related to the presence and extent of LGE and can significantly predict cardiovascular outcome. The joint use of LGE with Gal3 and PICP significantly improved outcome prediction.
No takes yet. Share an insight, caveat, or question.
Revnic et al. (2022) conducted a cohort in Non-ischemic dilated cardiomyopathy (NIDCM) (n=194). Elevated circulating collagen turnover biomarkers (Galectin-3 >13.8 ng/mL, PICP, PIIINP) and late gadolinium enhancement (LGE) on CMR vs. Lower biomarker levels (e.g., Galectin-3 ≤13.8 ng/mL) and absence of LGE (LGE-) was evaluated on Composite MACE outcome of all-cause mortality (or cardiac death/aborted death), sustained ventricular tachyarrhythmias, and heart failure hospitalization (HR 2.66, 95% CI 1.34-5.27, p=<0.001). Galectin-3 and LGE+ predicted composite major cardiovascular events in NIDCM patients and remained independent predictors after multivariate adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: